Aptose Biosciences (TSE:APS) Shares Pass Above 50-Day Moving Average – Should You Sell?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s stock price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$2.18 and traded as high as C$2.25. Aptose Biosciences shares last traded at C$2.25, with a volume of 101 shares traded.

Analyst Upgrades and Downgrades

Separately, Alliance Global Partners lowered Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company currently has an average rating of “Hold”.

Aptose Biosciences Trading Up 2.7%

The company has a debt-to-equity ratio of -117.37, a current ratio of 1.05 and a quick ratio of 5.41. The company has a market capitalization of C$5.74 million, a P/E ratio of 3.26 and a beta of -1.05. The firm has a fifty day moving average price of C$2.18 and a 200-day moving average price of C$1.95.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.